covaxin: Study: Covaxin third shot 90% effective | India News

HYDERABAD: A booster shot of indigenously developed vaccine Covaxin after two doses is able to generate robust antibody responses and neutralise the Omicron and Delta variants of Sars-CoV-2, a study conducted at Atlanta-based Emory University has found.
In the study, conducted by the Emory Vaccine Centre using a live virus neutralisation assay, 100% of the test serum samples showed neutralisation of the Delta variant and over 90% of serum samples showed neutralisation of Omicron Bharat Biotech said on Wednesday.
As part of the study, which is set to be published on pre-print server medRxiv soon, blood serum collected from 13 participants of Covaxin’s Phase-2 clinical trials (conducted in 2020) 28 days after they received their third shot (in 2021) was analysed for the neutralising response against the two variants.
All the participants had received the first two doses, 28 days apart and the third dose six months after the second dose. The study was sponsored by Bharat Biotech’s partner for US & Canada, Ocugen Inc.
Bharat Biotech said the study showed that neutralisation activity of Covaxin-boosted sera was comparable to what has been observed in mRNA vaccine-boosted sera against Omicron, with over 90% of all individuals boosted with Covaxin showing neutralising antibodies. “Data from this preliminary analysis show individuals receiving a booster dose of Covaxin have a significant immune response to both Omicron and Delta. These findings suggest that a booster dose has the potential to reduce disease severity and hospitalisations,” said Mehul Suthar, assistant professor at Emory University, who led the lab analysis.
Bharat Biotech said the latest data adds to the body of evidence that the broad-spectrum mechanism of action of a whole virus inactivated Covid-19 vaccine like Covaxin is a viable option in this continuously evolving pandemic.
“The positive neutralization responses against the Omicron and Delta variants, validates our hypothesis of a multi-epitope vaccine generating both humoral and cell mediated immune responses,” said Bharat Biotech chairman & managing director Dr Krishna Ella, adding that with Covaxin, the company has achieved its goal of developing a global universal vaccine for adults and children.

Leave a Reply

Your email address will not be published. Required fields are marked *

Previous post Virat Kohli and Cheteshwar Pujara have been headache for us, says South Africa batter Keegan Petersen | Cricket News
Next post El Clasico: Federico Valverde’s extra-time goal gives Real Madrid 3-2 win over Barcelona in Super Cup semis | Football News